An Approach to the Psychopharmacologic Care of Patients: Antidepressants, Antipsychotics, Anxiolytics, Mood Stabilizers, and Natural Remedies

Medical Clinics of North America

Volumn 94, Issue 6, 2010, Pages 1141-1160

  Huffman, Jeff C ^a,b   Alpert, Jonathan E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressants; Antipsychotics; Anxiolytics; Mood stabilizers; Natural remedies; Psychopharmacology

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLONAZEPAM; DESVENLAFAXINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; LORAZEPAM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OXAZEPAM; PAROXETINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM;

ANTICHOLINERGIC EFFECT; ANXIETY; ANXIETY DISORDER; APPETITE; ATAXIA; BLOOD PRESSURE; COGNITIVE THERAPY; CONFUSION; DEPRESSION; DIZZINESS; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MAJOR DEPRESSION; MEMORY DISORDER; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; NAUSEA; NEUROPATHIC PAIN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANIC; PATIENT CARE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STANDING; TASTE DISORDER; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; NATUROPATHY;

EID: 77957887113     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.08.009     Document Type: Review

References (32)

1. Altshuler L., Suppes T., Black D., et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003, 160(7):1252-1262.
2. Mander A.J., Loudon J.B. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988, 2(8601):15-17.
3. Viguera A.C., Whitfield T., Baldessarini R.J., et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007, 164(12):1817-1824. [quiz: 1923].
4. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000, 157(Suppl 4):1-45.
5. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354(12):1231-1242.
6. Trivedi M.H., Fava M., Wisniewski S.R., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354(12):1243-1252.
7. Ditto K.E. SSRI discontinuation syndrome. Awareness as an approach to prevention. Postgrad Med 2003, 114(2):79-84.
8. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23(6):493-509.
9. Cohen L.S., Altshuler L.L., Harlow B.L., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006, 295(5):499-507.
10. Perry R., Cassagnol M. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther 2009, 31(Pt 1):1374-1404.
11. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998, 59(10):502-508.
12. Madhusoodanan S., Bogunovic O.J. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 2004, 3(5):485-493.
13. Soumerai S.B., Simoni-Wastila L., Singer C., et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv 2003, 54(7):1006-1011.
14. Wikner B.N., Stiller C.O., Bergman U., et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16(11):1203-1210.
15. Victorri-Vigneau C., Dailly E., Veyrac G., et al. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007, 64(2):198-209.
16. Najjar M. Zolpidem and amnestic sleep related eating disorder. J Clin Sleep Med 2007, 3(6):637-638.
17. Hoque R., Chesson A.L. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009, 5(5):471-476.
18. Zammit G., Erman M., Wang-Weigand S., et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007, 3(5):495-504.
19. Kanno O., Sasaki T., Watanabe H., et al. Comparison of the effects of zolpidem and triazolam on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24(6):897-910.
20. Tondo L., Baldessarini R.J. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psichiatr Soc 2009, 18(3):179-183.
21. Pinelli J.M., Symington A.J., Cunningham K.A., et al. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 2002, 187(1):245-249.
22. Yonkers K.A., Wisner K.L., Stowe Z., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004, 161(4):608-620.
23. Nguyen H.T., Sharma V., McIntyre R.S. Teratogenesis associated with antibipolar agents. Adv Ther 2009, 26(3):281-294.
24. Naber D., Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009, 23(8):649-659.
25. Haddad P.M., Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007, 21(11):911-936.
26. Poulin M.J., Cortese L., Williams R., et al. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry 2005, 50(9):555-562.
27. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin North Am 2007, 30(1):51-68.
28. Papakostas G.I. Evidence for S-adenosyl-L-methionine (SAMe) for the treatment of major depressive disorder. J Clin Psychiatry 2009, 70(Suppl 5):18-22.
29. Freeman M.P. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009, 70(Suppl 5):7-11.
30. Linde K., Ramirez G., Mulrow C.D., et al. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 1996, 313(7052):253-258.
31. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008, 20(12):1182-1193.
32. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009, 1. CD003120.